The obesity treatment market, driven largely by advances in GLP-1–based drugs, has quickly become one of the most closely watched sectors in biopharma. Analyst consensus suggests that the next decade will bring extraordinary growth, with revenues expanding from today’s strong base into the tens of billions of dollars annually. Some long-term forecasts, such as that from Morgan Stanley, even project a market surpassing USD 150 billion by the mid-2030s, reflecting both the medical need and the commercial opportunity.
Beyond Weight Loss: A Broader Metabolic Market
While obesity remains the primary driver of current demand, many analysts highlight the broader therapeutic potential of GLP-1s. These assets are being studied not just for weight management, but also for conditions such as cardiovascular disease, chronic kidney disease and even neurological disorders. This shift reframes obesity drugs as part of a much larger “metabolic health” market, which significantly expands the potential patient base. For companies operating in this space, understanding where and how these adjacent applications could gain traction is central to long-term strategy.
Insights from Company Forecasts
Public company models reinforce the optimism but also reveal some of the challenges. Morgan Stanley, when looking at Novo Nordisk, the progenitor of Ozempic and Wegovy, has reported rapid expansion in its obesity segment, with the drugs pair now central to its financial outlook. From its obesity candidates, the Danish organization is forecasted to have a 120% increase in revenue from now until 2034. However, the model notes less reliance on Ozempic and the US market.
This assumption is partly taken into account with Eli Lilly increasingly gaining a foothold in the market thanks to their asset, tirzepatide, which has been predicted to overtake Ozempic in terms of revenue estimates by 2030.
Why Analyst Reports Matter
Numbers alone tell only part of the story. Analyst reports and forecast models provide valuable granularity, such as regional segmentation, uptake assumptions, pricing pressures and competitive positioning. They also map out risks and scenarios, from best-case blockbuster launches to setbacks due to reimbursement hurdles or safety data. For business development managers and decision-makers, these insights are indispensable. They aid in licensing decisions, partnership negotiations and serve as a benchmark for internal forecasts against independent, third-party perspectives.
Staying Current in a Fast-Moving Market
Few sectors evolve as quickly as obesity and metabolic health. Clinical trial readouts, regulatory approvals and reimbursement shifts can dramatically reshape market expectations in a matter of months. Having access to continuously updated intelligence is therefore crucial. Biotechgate’s Analyst Reports section provides precisely that: detailed research from top brokerage houses, complete with company forecast models and industry intelligence. For companies seeking to stay one step ahead, these resources serve as both a compass and a reality check in a market where expectations change rapidly.
What Next?
The obesity market is no longer a niche segment but a global growth engine that could reshape entire therapeutic areas. Analyst consensus points to massive upside, though accompanied by challenges in supply, pricing and competition. For companies, investors and BD&L teams, the key lies in separating hype from realistic projections – and that is where analyst reports and industry intelligence become invaluable.
For those looking to explore these trends in greater depth, request a demo of Biotechgate to see how our analyst reports suit you.